Compare IAF & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IAF | VANI |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 111.0M |
| IPO Year | N/A | 2014 |
| Metric | IAF | VANI |
|---|---|---|
| Price | $12.40 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 47.5K | ★ 157.7K |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | ★ 11.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.76 | $0.92 |
| 52 Week High | $14.54 | $1.66 |
| Indicator | IAF | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 32.53 |
| Support Level | $12.27 | $0.92 |
| Resistance Level | $12.87 | $1.12 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 17.02 | 12.50 |
Abrdn Australia Equity Fund Inc is a non-diversified closed-end management investment company. The Fund's principal investment objective is long-term capital appreciation through investment in equity securities of Australian companies listed on the Australian Stock Exchange Limited (ASX). Its secondary objective is current income, which is expected to be derived from dividends and interest on Australian corporate and governmental securities.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.